BioCardia, Inc (BCDAW)

Etorro trading 970x250

About BioCardia, Inc

BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived from mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system; and Morph vascular access product line, which provides catheter products. BioCardia, Inc. is based in San Carlos, California. Address:

BioCardia, Inc News and around…

Latest news about BioCardia, Inc (BCDAW) common stock and company :

BioCardia Issued New U.S. Patent for Technology that Enhances Control for Interventional Catheter Based Therapies
12 Oct, 2021 Yahoo! Finance

Technology Anticipated to Impact Cardiac Biologic Therapies, Transseptal Cardiac Procedures, and Other Interventional Catheter Based TherapiesSAN CARLOS, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a company focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the issuance of U.S. Patent No: 11,141,568 for “Multi Directional Steerable Catheter” that further protects the Helix™ Biothe

BioCardia Announces First Cross-Over Patient Treated in CardiAMP Cell Therapy Heart Failure Trial
07 Oct, 2021 Yahoo! Finance

SAN CARLOS, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the treatment of the first cross-over patient in the ongoing Phase III Pivotal CardiAMP® Cell Therapy in Heart Failure Trial for the treatment of ischemic heart failure. A cross-over patient is one who was previously in the control group of the study, has completed f

BioCardia Announces Participation at the A.G.P. Biotech & Specialty Pharma Conference October 13, 2021 (Virtual Conference)
06 Oct, 2021 Yahoo! Finance

SAN CARLOS, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular diseases, today announced it will be participating in the A.G.P Biotech & Specialty Pharma Conference taking place virtually on October 13, 2021. Dr. Peter Altman, CEO of BioCardia, will be participating in one-on-one meetings at the conference. If you are an institutional or retail investor, and would li

Here's Why We're Watching BioCardia's (NASDAQ:BCDA) Cash Burn Situation
28 Sep, 2021 Yahoo! Finance

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

CardiAMP Cell Therapy Heart Failure Trial to be Featured in Two Presentations at Heart Failure Society of America Annual Meeting 2021
10 Sep, 2021 Yahoo! Finance

SAN CARLOS, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces data from its CardiAMP® Cell Therapy Heart Failure pivotal trial (ClinicalTrials.gov Identifier: NCT02438306), which are being presented at the Heart Failure Society of America Annual Meeting 2021 on Saturday, September 11. This year’s meeting provides a hybrid for

BioCardia Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 (Virtual Conference)
09 Sep, 2021 Yahoo! Finance

SAN CARLOS, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), today announced it has recorded a company presentation that will be available on demand at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference. The conference is being held as a virtual conference on September 13-15, 2021. Dr. Peter Altman, CEO of BioCardia, will be participating in one-on-one meetings at the conference. If you are an institutional or retail investor, and would like to listen

Keynotes, Educational Panels and 60 Companies to Present at the SNN Network Summer Virtual Event on August 17-19, 2021
16 Aug, 2021 Yahoo! Finance

LOS ANGELES, CA / ACCESSWIRE / August 16, 2021 / The SNN Network Summer Virtual Event will take place on August 17-19, 2021, where 60 SmallCap, MicroCap and NanoCap public and private companies will be presenting via virtual webcast to a global investor audience.The SNN Network Summer Virtual Event begins on Tuesday, August 17, 2021 with the "MicroCap Investing Workshop" starting at 8:00am EST and featuring well-known financial influencers, investors, fund managers, and key opinion leaders, incl

BioCardia to Participate in Upcoming Investor Conferences
13 Aug, 2021 Yahoo! Finance

SAN CARLOS, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the Company’s management team will participate in the following upcoming investor conferences: Q3 Investor Summit Virtual Conference from August 17-18, 2021 https://investorsummitgroup.com/conferences/ BioCardia Corporate Presentation scheduled for 08/17 at 2pm Eastern Time (11

BioCardia Reports Second Quarter 2021 Financial Results and Business Highlights
12 Aug, 2021 Yahoo! Finance

SAN CARLOS, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2021 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2021 with the Securities and Exchange Commission. Q2 and Recent Business Highlights: CardiAMP® Autologous Cell Therapy for ischemic heart failure (B

BioCardia Announces Japanese Patent on Imaging System for Targeting Cardiac Therapies
15 Jul, 2021 Yahoo! Finance

SAN CARLOS, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the Japan Patent Office has granted Patent No: 6887216 titled, “Target Site Selection, Entry, and Update With Automatic Remote Image Annotation” with a patent term that will expire on January 8, 2034. “This patent describes advances for image guided delivery of treatments

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Heart Failure Study as Designed
17 Dec, 2020 FinancialContent
BioCardia Reports Third Quarter 2020 Financial Results and Business Highlights
10 Nov, 2020 FinancialContent
Published Peer-reviewed Initial Data from BioCardia Pivotal Phase 3 Clinical Trial of CardiAMP Demonstrates Improvement in Heart Failure Patients Measured by Exercise Outcomes and Cardiac Function
26 Oct, 2020 FinancialContent

BioCardia, Inc (BCDAW) is a NASDAQ Common Stock listed in ,

970x250